Last edition
News about Biotechnology
Innovent Biologics Licenses Anti-CD40L Therapy IBI355 to Spero Therapeutics in USD 1.1 Billion Deal
Innovent Biologics has licensed global rights outside Greater China for its anti-CD40L antibody IBI355 to Spero Therapeutics in a deal valued at up to USD 1.1 billion, advancing the development of a potential new treatment for autoimmune diseases including IgG4-related disease and Sjögren's disease.
Biotechnology | 15/07/2026 | By News Bureau | 211
Formycon and OneSource Partner to Manufacture Biosimilars
Formycon and OneSource Specialty Pharma have partnered to manufacture biosimilars, with OneSource providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing from its Bengaluru biologics facility.
Biotechnology | 15/07/2026 | By News Bureau | 120
Parexel Launches Biotech Incubator for Early-stage Innovators
Parexel has launched the Parexel Biotech Incubator to support early-stage therapeutics companies with clinical development expertise and strategic resources. The initiative includes a founding partnership with Cape Fear BioCapital to connect incubator to a seed-stage venture partner.
Biotechnology | 24/06/2026 | By News Bureau | 198
India Poised to Become a Global Biopharma Leader: Anupriya Patel
Union Minister Anupriya Patel said India is well-positioned to become a global biopharma leader, highlighting the Biopharma SHAKTI initiative’s goal of launching 100 biologics by 2047. She urged the industry to strengthen capabilities in biologics and biosimilars.
Biotechnology | 12/06/2026 | By News Bureau | 146
Roche and Nurix Partner to Develop BTK Degrader Bexobrutideg
Roche and Nurix Therapeutics have partnered to develop and commercialise bexobrutideg, a potential best-in-class BTK degrader for B-cell malignancies, chronic spontaneous urticaria, and Multiple Sclerosis (MS), aiming to overcome resistance to current BTK inhibitors.
Biotechnology | 09/06/2026 | By News Bureau | 153
Made Scientific and Pluristyx Partner to Advance iPSC Cell Therapies
Made Scientific and Pluristyx have launched a strategic partnership to streamline iPSC-derived cell therapy development and manufacturing. By integrating Pluristyx’s clinical-grade iPSC platform with Made Scientific’s CDMO services, the collaboration provides developers with a single-source pathway from cell line development to commercial supply.
Biotechnology | 08/06/2026 | By News Bureau | 154
Next-generation Nanomedicine can Silence Key Cancer Drivers: Research
Scientists in Pune have developed a next-generation precision nanomedicine that uses gene-silencing technology to target key cancer drivers and effectively inhibit breast tumor growth, highlighting a promising new approach for targeted breast cancer treatment and precision oncology.
Biotechnology | 04/06/2026 | By News Bureau | 136
Illumina Unveils Whole-Genome Sequencing Solution for Sensitive MRD Detection
Illumina has launched the first distributed Whole-Genome Sequencing (WGS) solution for highly sensitive Molecular Residual Disease (MRD) research, enabling faster and more flexible detection of the disease during and after treatment while expanding its next-generation oncology sequencing portfolio.
Biotechnology | 02/06/2026 | By News Bureau | 183
Leica Biosystems, AstraZeneca and Daiichi Sankyo have expanded their strategic collaboration to develop an AI-enabled immunohistochemistry assay and computational pathology solution for evaluating the TROP2 Normalised Membrane Ratio biomarker in NSCLC, aiming to advance biomarker-driven cancer research and future precision medicine approaches.<br />
Biotechnology | 01/06/2026 | By News Bureau | 176
Parse Biosciences and bit.bio have announced a strategic alliance to develop a comprehensive transcription factor-driven cell identity map, leveraging advanced single-cell sequencing and cell programming technologies to improve predictive drug discovery and scalable therapeutic research.
Biotechnology | 29/05/2026 | By News Bureau | 145
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy